General Information of Drug (ID: DMPCFXN)

Drug Name
QAW-039 Drug Info
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 3 [1]
Cross-matching ID
PubChem CID
23582412
TTD Drug ID
DMPCFXN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LAROPIPRANT DM5FABJ Coronary heart disease BA80.Z Phase 4 [3]
Setipiprant DMZ61IA Asthma CA23 Phase 3 [4]
AMG 853 DM973N4 Asthma CA23 Phase 2 [5]
ONO-4053 DMX4MVP Allergic rhinitis CA08.0 Phase 2 [6]
TS-022 DMMNXIW Atopic dermatitis EA80 Phase 2 [7]
S-555739 DMXDVNZ Allergy 4A80-4A85 Phase 2 [8]
MK-1029 DM8ZTW7 Asthma CA23 Phase 2 [9]
SAR-389644 DMA6O9R Allergic rhinitis CA08.0 Phase 1 [10]
192C86 DMQ8NTZ Thrombosis DB61-GB90 Phase 1 [11]
MK-1092 DMHS79I Type-1 diabetes 5A10 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin D2 receptor (PTGDR) TTNVEIR PD2R_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT02563067) Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
2 Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015.
3 Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45.
6 Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219.
7 Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14.
8 Clinical pipeline report, company report or official report of Shionogi (2011).
9 Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66.
10 US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders.
11 Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145.
12 The challenge of modulating -cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64.